stockrowSummit Therapeutics PLC
SMMT Healthcare Biotechnology
Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00.
- EPS
- +63.2%
- Free cash flow
- −112.8%
Quarter to June 2026, against a year earlier
Follow SMMT
Alert me
Summit Therapeutics PLC (SMMT) P/B ratio
As of 5 November 2026, Summit Therapeutics PLC (SMMT) trades at a P/B ratio of 17.8×. Over the past ten years it has ranged from 0.0× (July 2017) to 173× (May 2024); the current reading is higher than 71% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2022 | 7.6× | 79.41% |
| FY2021 | 4.3× | 3.44% |
| FY2020 | 4.1× | 517.52% |
| FY2019 | 0.7× | 63.48% |
| FY2019 | 0.4× | (21.58%) |
| FY2018 | 0.5× | (96.28%) |
| FY2018 | 14.0× | 102.31% |
| FY2017 | 6.9× | — |
| FY2017 | 0.0× | — |
| FY2016 | 78.4× | — |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Dec 2022 | 7.6× | 309.09% |
| Sep 2022 | 1.9× | (31.67%) |
| Jun 2022 | 2.7× | (48.74%) |
| Mar 2022 | 5.3× | 25.22% |
| 23 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| HALO Halozyme Therapeutics, Inc. compare | n/m |
| BBIO BridgeBio Pharma, Inc. compare | n/m |
| BMRN BioMarin Pharmaceutical Inc. compare | 1.7× |
| PCVX Vaxcyte, Inc. compare | 3.3× |
| JAZZ Jazz Pharmaceuticals PLC compare | 3.5× |
| TECH Bio-Techne Corp compare | 5.4× |
| KYMR Kymera Therapeutics, Inc. compare | 7.8× |
| ASND Ascendis Pharma A/S compare | 9.8× |
| SMMT Summit Therapeutics PLC | 17.8× |
| Biotechnology industry median | 2.0× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on SMMT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement